ARIPIPRAZOLE-ZP aripiprazole 30mg tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

aripiprazole, Quantity: 30 mg

Disponível em:

Medis Pharma Pty Ltd

DCI (Denominação Comum Internacional):

aripiprazole

Forma farmacêutica:

Tablet, uncoated

Composição:

Excipient Ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; magnesium stearate; hyprolose

Via de administração:

Oral

Unidades em pacote:

30

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,Acute treatment of manic or mixed episodes associated with Bipolar I Disorder in adults as monotherapy and in combination with lithium or valproate;,Maintenance treatment of manic or mixed episodes in Bipolar I Disorder in adults as monotherapy.

Resumo do produto:

Visual Identification: 9mm, round, biconvex, white uncoated tablets with 30 debossed on one side and ZL on the other side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2014-10-29